APR 14, 2017 11:31 AM PDT

New in Immunotherapy: Blocking Cancer Blood Vessels

WRITTEN BY: Kara Marker

Immunotherapy is a method of fighting cancer that revolves around empowering the immune system to reach its full cancer-killing potential. But tumor cells are constantly finding ways to resist and retaliate, so counterattacks are always necessary.

An antibody against ANGPT2 and VEGFA reprograms the tumor blood vessels to facilitate the extravasation of anti-tumoral T cells. Credit: Ella Maru Studio

A growing tumor generates its own system of blood vessels that flood cancer cells with oxygen and nutrients. In addition to providing nourishment, these vessels block the arrival of T cells either naturally sent by the immune system or sent as a result of an immunotherapy to boost T cell activity. Tumors rely on two key proteins to stimulate the growth of their blood vessel network and to keep T cells at bay: VEGFA and ANGPT2.

A new approach designed by experts from the Ecole Polytechnique Federale De Lausanne (EPFL) in Switzerland may be the answer: an antibody called A2V that simultaneously blocks VEGFA and ANGPT2 and metastasis.

"A2V not only regressed most of the tumor blood vessels, but also reversed the aberrant features of those that had remained, making them similar to normal blood vessels and more permissive to the arrival of anti-tumoral T cells,” explained study leader Michele De Palma.

By preventing tumors from reaping the benefits of their blood vessel system, A2V offers a new solution for treating many different types of cancer. However, the EPFL study showed that tumors were quick to answer back with a solution of their own: expression of protein PD-L1 that binds to PD-1 on the surface of T cells to prevent T cells from attacking. Thankfully, scientists have already developed antibodies that serve as checkpoint inhibitors to counter the PD-L1/PD-1 inhibition of T cells.

“Certain anti-angiogenic drugs, namely ANGPT2 inhibitors, have more profound effects on tumors than initially thought,” De Palma explained. “Besides targeting the blood vessels, they also help initiate anti-tumoral immune responses, which can be reinforced by immune checkpoint blockade.”

Based on De Palma’s findings, it seems that scientists are just unveiling the beginning of the potential benefits of applying the A2V antibody. Future studies will illustrate just how valuable this new approach will be for fighting cancer.

The present study was published in the journal Science Translational Medicine. For more on cancer immunotherapy, check out the video below: 

Sources: Ecole Polytechnique Federale De Lausanne (EPFL)

About the Author
  • I am a scientific journalist and enthusiast, especially in the realm of biomedicine. I am passionate about conveying the truth in scientific phenomena and subsequently improving health and public awareness. Sometimes scientific research needs a translator to effectively communicate the scientific jargon present in significant findings. I plan to be that translating communicator, and I hope to decrease the spread of misrepresented scientific phenomena! Check out my science blog: ScienceKara.com.
You May Also Like
MAY 24, 2018
Immunology
MAY 24, 2018
The Link Between Tuberculosis and Parkinson Disease
There might be a link between Tuberculosis (TB) and Parkinson’s according to a study published in The EMBO Journal. This link is related to the mecha...
JUN 05, 2018
Clinical & Molecular DX
JUN 05, 2018
"ImmunoPET" Imaging Identifies IBD Inflammation
Scientists are now applying PET imaging to detect inflammation in people with inflammatory bowel disease (IBD). This could help countless IBD patients conn...
JUN 18, 2018
Immunology
JUN 18, 2018
Detecting and Diagnosing Rheumatoid Arthritis Before it Begins
Unique gene signatures and tiny changes in the immune system that occur in the earliest stages of rheumatoid arthritis, an autoimmune disease, could soon b...
JUL 09, 2018
Immunology
JUL 09, 2018
Protein Complex Determines the Fate of T cells
The protein complex mTORC1 has been shown to integrate metabolic and signaling activity to determine the fate of T cell lineage between alpha beta and gamma delta....
JUL 17, 2018
Immunology
JUL 17, 2018
Powering up the Elderly's Immune System
Use of drugs that inhibit the TORC1 pathway has bolstered the immune systems of the elderly, leading to a decrease in potentially deadly infections such as pneumonia and influenza....
AUG 15, 2018
Immunology
AUG 15, 2018
Therapeutic Macrophages Improve Rare Lung Disorder
The use of therapeutic macrophage transplantation in mice showed great improvement in rare lung disorder caused by deficient macrophages....
Loading Comments...